Core Insights - CalciMedica Inc. is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases [3] Company Overview - CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury [3] - The company aims to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies [3] - CalciMedica's lead product candidate, Auxora™, has shown positive and consistent clinical results in multiple completed efficacy clinical trials [3] Clinical Trials - The company has announced topline data for a Phase 2b trial (CARPO – NCT04681066) in patients with acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS) [3] - A Phase 2 trial (CARDEA – NCT04345614) in patients with COVID pneumonia has been completed [3] - Currently, CalciMedica is conducting a Phase 2 trial (KOURAGE – NCT06374797) in patients with acute kidney injury (AKI) with associated acute hypoxic respiratory failure (AHRF), with data expected in 2025 [3] - The company is also supporting an ongoing Phase 1/2 trial (CRSPA – NCT04195347) in patients with acute inflammatory pulmonary thrombosis (AIPT), with data also expected in 2025 [3] Upcoming Events - Rachel Leheny, Ph.D., CEO of CalciMedica, will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024 [1]
CalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment Conference